PEPG at a glance
PepGen Inc (PEPG, SEC CIK 1835597) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 14 institutional investment managers tracked by SignalX reported holding PepGen Inc (PEPG) shares worth $23.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on November 13, 2026 of 8,625,000 shares at $5.00 per share.
- In the last 90 days, PEPG insiders reported 1 open-market purchase ($43.1M) and 0 open-market sales ($0) on Form 4, a net purchase of $43.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$43.1M
- 13F holders
- 14 funds
- $23.9M · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 1.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales since inception
- Net loss $19.4M vs $18.0M YoY, operating loss $20.4M vs $18.7M
- R&D expense $14.5M vs $13.4M, PGN-EDODM1 external expense $7.7M vs $5.4M
- Cash, equivalents and marketable securities $104.8M at September 30, 2026, funding planned operations into 2028
- Operating cash use $47.4M for nine months, ATM proceeds $1.5M, FREEDOM2 remains on partial U.S. clinical hold
Risk Factors
- Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 Section 1260H designation could trigger OMB BCC designation and supplier transition costs
- Regulatory risk: FDA partial clinical hold announced March 2026 requires additional nonclinical mouse studies for FREEDOM2
- Operational risk: Single-source API and finished-product suppliers could disrupt PGN-EDODM1 clinical development
- Financial risk: $104.8 million cash, equivalents and marketable securities as of September 30, 2026, with additional funding needed beyond 2026 readouts
- Market risk: PGN-EDODM1 remains PepGen’s only active clinical program after PGN-EDO51 discontinuation in May 2025
AI summary of the PEPG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Proposed $125.0 million common-stock offering, primarily funding clinical development and corporate needs
- Underwriters’ 30-day option could add $18.75 million, increasing potential proceeds
Item EX-99.2: Item EX-99.2
- $125 million gross equity offering: 25,000,000 shares priced at $5.00 each
- Potential additional dilution: underwriters hold a 30-day option for 3,750,000 shares
Item 1.01: Entry into a Material Definitive Agreement
- $125.0 million common-stock offering: 25.0 million shares at $5.00 each
- Underwriters’ 30-day option for 3.75 million additional shares, potentially increasing gross proceeds by $18.75 million
Item 8.01: Other Events
- PepGen launched a securities offering on November 10, 2026
- Offering pricing announced November 11, 2026
Item 2.02: Results of Operations and Financial Condition
- PepGen announced third-quarter 2026 financial results for the period ended September 30, 2026
- Press release highlights recent corporate developments alongside quarterly results
Item 7.01: Regulation FD Disclosure
- PepGen announced positive Phase 2 FREEDOM2-DM1 results for a 10mg/kg dose
- Results reportedly showed the highest reported splicing correction in the program
Item 8.01: Other Events
- Investor presentation updates FREEDOM2-DM1 data for the 10 mg/kg multiple-ascending-dose cohort
- Materials support investor discussions and may influence views on PepGen’s DM1 clinical progress
Item EX-99.1: Item EX-99.1
- 10 mg/kg cohort showed 46.5% mean splicing correction, with functional improvements across mobility, grip strength and hand opening
- Safety remained favorable: no treatment discontinuations, serious or severe adverse events, or dose-limiting toxicities at 10 mg/kg
Item EX-99.3: Item EX-99.3
- 10 mg/kg cohort showed 46.5% mean splicing correction at Week 13, with 4 of 6 patients exceeding 50%
- Functional improvements at 10 mg/kg: vHOT improved 4.3 seconds at Week 13 and 3.9 seconds at Week 16
Item EX-99.2: Item EX-99.2
- Phase 2 10 mg/kg cohort showed 46.5% mean splicing correction at Week 13, with four of six participants exceeding 50%
- Functional gains at Week 16: vHOT improved 52.7%, grip strength 16.2%, TUG 8.5%, and 10MWRT 6.8%
Item 2.02: Results of Operations and Financial Condition
- PepGen announced second-quarter 2026 financial results for the quarter ended June 30, 2026
- Press release also covers recent corporate highlights, providing investors operational updates beyond financial results
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation reflects PepGen’s recent corporate updates as of August 6, 2026
- Exhibit 99.2 contains the presentation, potentially including updated strategic, clinical, or financial information
Item 8.01: Other Events
- DSMB cleared FREEDOM2-DM1’s highest MAD cohort, advancing dosing to 12.5 mg/kg
- No protocol changes recommended, supporting continued execution of the Phase 2 study
Item EX-99.1: Item EX-99.1
- DSMB-cleared escalation to 12.5 mg/kg, supporting continued clinical development of PGN-EDODM1 in DM1
- 10 mg/kg cohort fully enrolled, with 7 of 8 participants dosed; data expected November 2026
Item EX-99.2: Item EX-99.2
- PGN-EDODM1 showed dose-dependent single-dose splicing correction, reaching 53.7% mean improvement at 15 mg/kg and 83% of patients exceeding 20% correction
- FREEDOM2 5 mg/kg repeat dosing produced 22.9% mean splicing correction excluding one outlier, with promising vHOT myotonia trends
Item EX-99.3: Item EX-99.3
- DSMB cleared PGN-EDODM1 advancement to the highest planned 12.5 mg/kg cohort in Phase 2 FREEDOM2-DM1
- Safety review found no serious adverse events, dose-limiting toxicities, cumulative toxicity, or treatment discontinuations
AI summaries of PEPG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PEPG
Don't miss the next PEPG filing
- Alerts as it files. A push when PEPG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PEPG, by share count.
- Ask anything. An AI agent that reads every PEPG filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Buy | Nov 13, 2026 | 8,625,000 | $5.00 |
| Mayer Howard | A | Jun 18, 2026 | 34,000 | - |
| KEATING LAURIE | A | Jun 18, 2026 | 34,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | A | Jun 18, 2026 | 34,000 | - |
| Finer Mitchell H. | A | Jun 18, 2026 | 34,000 | - |
| Dable Habib J | A | Jun 18, 2026 | 34,000 | - |
| HENSON HEIDI | A | Jun 18, 2026 | 34,000 | - |
| Wyman Lisa | A | Jun 18, 2026 | 34,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$84.8M | -$97.7M | -$93.6M |
| Net Income | -$78.6M | -$90.0M | -$89.7M |
| Balance Sheet | |||
| Total Assets | - | $150.9M | $173.9M |
| Equity | $108.4M | $118.6M | $147.4M |
| ROE | -72.5% | -75.9% | -60.8% |
| Per Share | |||
| EPS | $-3.30 | $-2.85 | $-2.12 |
| Cash Flow | |||
| Operating CF | -$69.0M | -$82.4M | -$81.6M |
| CapEx | $2.6M | $497K | $264K |
Source: XBRL data in PepGen Inc (PEPG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PEPG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 14 | $23.9M |
| Q2 2026 | 15 | $20.5M |
| Q1 2026 | 17 | $19.5M |
| Q4 2025 | 16 | $65.2M |
| Q3 2025 | 15 | $34.7M |
| Q2 2025 | 18 | $5.6M |
| Q1 2025 | 19 | $6.2M |
| Q4 2024 | 11 | $11.9M |
- Dimensional Fund Advisors+127.0K (+235%)
- BlackRock+42.0K (+3%)
- Vanguard Capital Management LLC+41.1K (+2%)
- Citigroup+33.7K (+2072%)
- JPMorgan Chase & Co+4.1K (+81%)
- Millennium Management−648.1K (-36%)
- Renaissance Technologies LLC−639.5K (-42%)
- Citadel Advisors LLC−259.1K (-39%)
- Goldman Sachs Group−73.3K (-44%)
- Two Sigma Investments−48.6K (-73%)
- FMR LLC (Fidelity)−1.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 125 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PEPG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | May 26, 2026 | - | - | |
| 8-K | May 21, 2026 | - | - | |
| 8-K | May 12, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | - | |
| 8-K | Mar 30, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 10-K | Mar 4, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PEPG SEC filings: frequently asked questions
Are PEPG insiders buying or selling?
In the last 90 days, PepGen Inc (PEPG) officers, directors and 10% owners reported 1 open-market purchase worth $43.1 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PEPG stock?
As of September 30, 2026, the largest PepGen Inc (PEPG) holders among the 13F filers tracked by SignalX were Viking Global Investors ($8.4 million), Vanguard Capital Management LLC ($4.8 million), BlackRock ($3.3 million), Millennium Management ($2.8 million), Renaissance Technologies LLC ($2.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did PEPG report in its latest 8-K?
PepGen Inc (PEPG) filed an 8-K on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). Proposed $125.0 million common-stock offering, primarily funding clinical development and corporate needs.
What are the latest PEPG SEC filings?
PepGen Inc (PEPG) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 17, 2026.
What is PEPG's SEC CIK number?
PepGen Inc (PEPG)'s SEC Central Index Key (CIK) is 1835597. EDGAR lists every PEPG filing under that number.
Ask anything about PEPG
The research agent reads PEPG's filings, financials, insider trades and 13F holders, then answers with sources.